Solanezumab for Alzheimer's disease

Bibliography

• Alzheimer's Disease Facts and Figures. Chicago, IL: Alzheimer's Association, 2010. Available from: http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf [Last accessed 5 March 2011]
   Google Scholar
• Changing the Trajectory of Alzheimer's Disease: a National Imperative. Chicago, IL: Alzheimer's Association, 2010. Available from: http://www.alz.org/documents_custom/trajectory.pdf [Last accessed 5 March 2011]
   Google Scholar
• Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44
   PubMed Web of Science ®Google Scholar
• Bales KR, Dodart JC, DeMattos RB, Apolipoprotein E, amyloid, and Alzheimer disease. Mol Interv 2002;2:363-75, 339
   PubMedGoogle Scholar
• Boche D, Nicoll JA, Weller RO. Immunotherapy for Alzheimer's disease and other dementias. Clin Neuropharmacol 2006;29:22-7
   PubMed Web of Science ®Google Scholar
• Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005;331:321-7
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24
   PubMed Web of Science ®Google Scholar
• Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007;6:341-2
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Black SE, Hendrix SB, Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008;7:483-93
   PubMed Web of Science ®Google Scholar
• Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med 2009;7:7
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Panza F, Frisardi V, Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 2011;20:325-41
   PubMed Web of Science ®Google Scholar
• Luo X, Yan R. Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Int J Clin Exp Pathol 2010;3:618-28
   PubMed Web of Science ®Google Scholar
• Gervais F. GAG mimetics: potential to modify underlying disease process in AD. Neurobiol Aging 2004;25:S11-12
   Web of Science ®Google Scholar
• Faux NG, Ritchie CW, Gunn A, PBT2 rapidly improves cognition in Alzheimer's Disease: additional Phase II analyses. J Alzheimers Dis 2010;20:509-16
   PubMed Web of Science ®Google Scholar
• Doody RS, Gavrilova SI, Sano M, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-15
   PubMed Web of Science ®Google Scholar
• Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect 2010;23:518-23
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-19
   PubMed Web of Science ®Google Scholar
• Chauhan NB, Siegel GJ. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res 2003;74:142-7
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Munireddy SK, Rosenthal A, Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 2004;15:11-20
   PubMed Web of Science ®Google Scholar
• Bayer AJ, Bullock R, Jones RW, Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005;64:94-101
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54
   PubMed Web of Science ®Google Scholar
• Woodhouse A, Dickson TC, Vickers JC. Vaccination strategies for Alzheimer's disease: a new hope? Drugs Aging 2007;24:107-19
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-52
   PubMed Web of Science ®Google Scholar
• Masliah E, Hansen L, Adame A, Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005;64:129-31
   PubMed Web of Science ®Google Scholar
• Holmes C, Boche D, Wilkinson D, Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-23
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Knopman DS, Jagust WJ Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. Abeta Oligomers – a decade of discovery. J Neurochem 2007;101:1172-84
   PubMed Web of Science ®Google Scholar
• Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009;110:1129-34
   PubMed Web of Science ®Google Scholar
• Tabira T. Development of new drugs for Alzheimer's disease. Brain Nerve 2010;62:787-96
   PubMedGoogle Scholar
• Dodel R, Neff F, Noelker C, Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 2010;70:513-28
   PubMed Web of Science ®Google Scholar
• Dodel RC, Du Y, Depboylu C, Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1472-4
   PubMed Web of Science ®Google Scholar
• Bales KR, Tzavara ET, Wu S, Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Abeta antibody. J Clin Invest 2006;116:825-32
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, Peripheral anti-Abeta anitibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:50-5
   Google Scholar
• Dodart JC, Bales KR, Gannon KS, Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-7
   PubMed Web of Science ®Google Scholar
• Lee HG, Zhu X, Nunomura A, Amyloid beta: the alternate hypothesis. Curr Alzheimer Res 2006;3:75-80
   PubMedGoogle Scholar
• Castellani RJ, Lee HG, Zhu X, Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol 2008;67:523-31
   PubMed Web of Science ®Google Scholar
• Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 1997;94:4109-12
   PubMed Web of Science ®Google Scholar
• Yamada K, Yabuki C, Seubert P, Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 2009;29:11393-8
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Gilman S, A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Dean RA, Friedrich S, Alterations of novel Abeta biomarkers after administration of a monoclonal antibody specific for soluble Abeta. Hot topics presentation, International Conference on Alzheimer's Disease; Chicago, IL; 2008
   Google Scholar
• Siemers ER, Friedrich S, Dean RA, Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33:67-73
   PubMed Web of Science ®Google Scholar
• Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin Biol Ther 2010;10:1121-30
   PubMed Web of Science ®Google Scholar
• Tariot PN, Schneider LS, Mintzer JE, Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Res 2001;62:51-67
   Web of Science ®Google Scholar
• Siemers ER, Friedrich S, Dean RA, Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimers Demen 2008;4(Suppl 2):T774
   Google Scholar
• Eli Lilly and Co. Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION). ClinicalTrials.gov NCT00905372. Available from: http://clinicaltrials.gov/ct2/show/NCT00905372?term=NCT00905372&rank=1
   Google Scholar
• Eli Lilly and Co. Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION2). ClinicalTrials.gov NCT00904683. Available from: http://clinicaltrials.gov/ct2/show/NCT00904683?term=NCT00904683&rank=1
   Google Scholar
• Eli Lilly and Co. Continued Safety Monitoring of Solanezumab in Alzheimer's Disease (EXPEDITION EXT). ClinicalTrials.gov NCT01127633. Available from: http://clinicaltrials.gov/ct2/show/NCT01127633?term=NCT01127633&rank=1
   Google Scholar
• Racke MM, Boone LI, Hepburn DL, Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005;25:629-36
   PubMed Web of Science ®Google Scholar
• Goto T, Fukjikoshi S, Uenaka K, Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study. International Conference on Alzheimer's Disease; Honolulu, HI; 2010. Alzheimers Demen 2010;6(4 Suppl):S308
   Google Scholar
• Eli Lilly and Co. A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's. ClinicalTrials.gov NCT01148498. Available from: http://clinicaltrials.gov/ct2/show/NCT01148498?term=NCT01148498&rank=1
   Google Scholar
• Rinne JO, Brooks DJ, Rossor MN, 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72
   PubMed Web of Science ®Google Scholar
• Erten-Lyons D, Woltjer RL, Dodge H, Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 2009;72:354-60
   PubMed Web of Science ®Google Scholar
• Scolnik PA. mAbs: a business perspective. MAbs 2009;1:179-84
   PubMed Web of Science ®Google Scholar